Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Clarithromycin XL on Topical Diltiazem in Healthy Subjects
NCT02080780Phase 1Completed
- Sponsor
- Ventrus Biosciences, Inc.
- Start
- Sep 2013
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DOLIZEM in anal fissure, sponsored by Ventrus Biosciences, Inc. Primary endpoint: Peak Plasma Concentration of 2% Diltiazem at 9 days. Started Sep 2013; status: completed.
02
Drugs
DOLIZEM
03
Conditions
anal fissure
Beyond the preview
Go deeper on NCT02080780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02080780.